Immunity Markers in Intensive Care Patients and Ventilator-associated Pneumonia
Key facts
- Who runs it
- Centre Hospitalier Intercommunal Aix-Pertuis
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 40 people, planned
- Started
- 4 Oct 2023
- Expected to end
- Dec 2026
- Type of study
- Observational
- Treatments tested
- Blood collection
- Record updated
- 26 August 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Patient over 18 years old
- Patient admitted in the Intensive Care Unit of the CHIAP
- Patient under mechanical ventilation
- Patient with infectious pneumonia
- Informed Consent Form (ICF) obtained from the patient or emergency ICF obtained from close relatives
- Patient beneficiary of French social security, whatever the regime
Who cannot take part
- Use of corticosteroids (intravenous or oral) prior to ICU admission
- Use of therapeutic antibodies
- Onco-hematological disease (e.g. lymphoma, leukemia...) under treatment or treated in the 5 years prior to inclusion
- End of chemotherapy 6 months prior to inclusion
- Patients with a decision to limit or discontinue active therapies, at the time of inclusion
- Patients with innate or acquired immune deficiency (e.g., severe combined immunodeficiency, HIV or AIDS, at any stage)
- Patient with severe neutropenia (neutrophils < 0.5 G/L)
- Patient under 18 years old
- Patient under immunosuppressive treatment
- Patients with an estimated ICU stay of less than 48 hours
- Participation in an interventional study
- Patient deprived of their liberty
- Patient under tutorship or curatorship
- Pregnant or breastfeeding woman
This trial is currently available in France.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this observational study is to show the direct correlation between the occurrence of recurrence of VAP and postagressive immunoparalysis, monitored by HLA-DR rate below litterature-acknowledged threshold, in a well conducted antibiotherapy context, in patient admitted in the Intensive Care Unit.
Read full original descriptionShow less
The main questions it aims to answer are:
* evaluation of the association between death and persistence of immunoplegia using HLA-DR monitoring * search an association between immunoplegia depth and severity of the initial state of shock * search an association between immunoplegia depth and viral reactivation * compare association of immunoplegia duration and HLA-DR nadir and VAP occurrence Blood samples will be taken from participants to HLA-DR dosage, at the time of inclusion and once a week then.
The group in the trial
- Interventional - blood collection
HLA-DR dosage, at the time of inclusion and once a week then
Treatment: Blood collection
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Monitoring of Immunity Markers in Intensive Care Patients and Link With Recurrence and Relapse of Ventilator-associated Pneumonia
- Record updated
- 26 August 2026